What it is
Ipamorelin is a synthetic pentapeptide studied for its interaction with the growth-hormone secretagogue receptor pathway. It is research material, not a validated treatment or a promise of a particular endocrine outcome.
Mechanism and research questions
- Ipamorelin is studied as an agonist of the growth-hormone secretagogue receptor pathway, commonly identified as GHS-R1a, the receptor associated with ghrelin signaling.
- Activation of this pathway is studied for stimulating growth-hormone release from pituitary somatotrophs in cellular, animal, and human pharmacology research.
- Growth hormone can act within the broader GH/IGF-1 axis, but this profile does not claim that catalog material raises IGF-1 to a specific level or produces a particular outcome.
- The receptor system is expressed in multiple tissues; no gut-specific mechanism or clinical effect is assigned to this catalog preparation.
Human evidence
A small study in healthy volunteers characterized ipamorelin exposure and episodic GH response. It did not establish a treatment benefit, a target IGF-1 level, or a protocol for catalog material.
Preclinical / mechanistic evidence
The discovery study examined GH release from rat pituitary cells and GH responses in rats and swine. Those findings describe pharmacology, not human efficacy or a safe-use protocol.
Evidence summary
The literature includes receptor pharmacology, animal studies, and a human pharmacokinetic/pharmacodynamic study of GH response. These studies do not establish an approved use or a benefit for research-vial material.
Limits and interpretation
- GH release is a measured pharmacologic response, not proof of a therapeutic benefit or a desirable IGF-1 outcome.
- Do not describe ipamorelin as producing high IGF-1, muscle gain, fat loss, recovery, anti-aging, or performance results.
- Do not combine evidence from different secretagogues without direct studies.
- Sequence, purity, stability, route, and preparation quality must be evaluated separately for each batch.
- No dosing or medical-use protocol is provided.
Regulatory and identity note
Research-use peptide; not presented as approved therapy.